A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy

被引：0
|
作者：
Khambati, Fatema [1 ]
Soliman, Hatem [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2395
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
    Stieglmaier, Julia
    Benjamin, Jonathan
    Nagorsen, Dirk
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1093 - 1099
  • [2] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [3] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [4] Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
    Zhu, Min
    Wu, Benjamin
    Brandl, Christian
    Johnson, Jessica
    Wolf, Andreas
    Chow, Andrew
    Doshi, Sameer
    CLINICAL PHARMACOKINETICS, 2016, 55 (10) : 1271 - 1288
  • [5] Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
    Min Zhu
    Benjamin Wu
    Christian Brandl
    Jessica Johnson
    Andreas Wolf
    Andrew Chow
    Sameer Doshi
    Clinical Pharmacokinetics, 2016, 55 : 1271 - 1288
  • [6] T-cell based cancer immunotherapy with a bispecific antibody directed at CD3 and EGFR.
    Reusch, U
    Olson, S
    Davis, J
    Davol, P
    Sundarum, M
    Liu, P
    Lum, LG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 178S - 178S
  • [7] The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
    Suurs, Frans, V
    Lorenczewski, Grit
    Stienen, Sabine
    Friedrich, Matthias
    de Vries, Elisabeth G. E.
    de Groot, Derk Jan A.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1594 - 1601
  • [8] Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
    Laszlo, George S.
    Gudgeon, Chelsea J.
    Harrington, Kimberly H.
    Dell'Aringa, Justine
    Newhall, Kathryn J.
    Means, Gary D.
    Sinclair, Angus M.
    Kischel, Roman
    Frankel, Stanley R.
    Walter, Roland B.
    BLOOD, 2014, 123 (04) : 554 - 561
  • [9] Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
    Sangsuwannukul, Thanich
    Supimon, Kamonlapat
    Chieochansin, Thaweesak
    Choomee, Kornkan
    Sujjitjoon, Jatuporn
    Junking, Mutita
    Yenchitsomanus, Pa-Thai
    PLOS ONE, 2022, 17 (03):
  • [10] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
    Reed, Daniel R.
    Lum, Lawrence G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
12345